HIV treatment failure: testing for HIV resistance in clinical practice.
about
Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 useOnly slight impact of predicted replicative capacity for therapy response predictionDifferential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and CSignificantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram dataModeling-error robustness of a viral-load preconditioning strategy for HIV treatment switching.High-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1.Resistance to nucleoside analog reverse transcriptase inhibitors mediated by human immunodeficiency virus type 1 p6 protein.Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals.How an inhibitor of the HIV-I protease modulates proteasome activity.Monitoring patients with HIV diseaseManagement of the adverse effects of antiretroviral therapy and medication adherence.Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 proteaseSensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli.Effect of Education of Primary Health Care Workers on HIV-related Oral Lesions in Nairobi East DistrictActinomycin D induces high-level resistance to thymidine analogs in replication of human immunodeficiency virus type 1 by interfering with host cell thymidine kinase expression.Cytokine therapy or structured treatment interruptions in HIV infection: which is best?Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.Production of resistant HIV mutants during antiretroviral therapy.Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypesPredicting drug resistance of the HIV-1 protease using molecular interaction energy components.HIV-1 genotyping: comparison of two commercially available assays.Health and economic benefits of an accelerated program of research to combat global infectious diseases.Bioinformatics approach to predicting HIV drug resistance.Vision function in HIV-infected individuals without retinitis: report of the Studies of Ocular Complications of AIDS Research GroupAn inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.Progress towards an HIV vaccine based on recombinant bacillus Calmette-Guérin: failures and challenges.Novel enzyme-linked minisequence assay for genotypic analysis of human immunodeficiency virus type 1 drug resistance.Controlling the Evolution of ResistanceDescription of two commercially available assays for genotyping of HIV-1.Antiviral potency of HAART regimens and clinical success are not strictly coupled in real life conditions: evidence from the MASTER-1 study.Identifying the optimal dose of ritonavir in the treatment of malignancies.The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivoLentiviral transduction of human T-lymphocytes with a RANTES intrakine inhibits human immunodeficiency virus type 1 infection.Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patientsStructure-activity relationship studies on a novel family of specific HIV-1 reverse transcriptase inhibitors.Novel strategy for anti-HIV-1 action: selective cytotoxic effect of N-myristoyltransferase inhibitor on HIV-1-infected cells.Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance Profiles.
P2860
Q24534863-09560EE7-8E12-45A5-B34A-F6246837DF85Q28344746-4AE61CA4-9AB4-4E22-8ACC-380B7C0DABA5Q28472749-D21FEB60-D635-4313-98B7-39E51ADEA116Q28484213-28D4FACD-8F86-441A-B039-4A2139DE7951Q28486299-5DAE5729-510B-436B-A648-17F4A788ED41Q33771799-794AAB29-96C1-4094-A4A4-ACC2FE7F0391Q33796791-ABB9C0C2-B809-464A-8605-8AFC49FFFEA4Q33838311-CC919E10-E688-4629-9159-26CF88F60C56Q33846417-71F65226-D4EA-4546-BE67-7B25AF00BE6CQ33850510-0BAF91C2-3A9E-4A93-9179-9958BF0234AFQ33882609-CC5C0BCF-B66C-472D-AC11-C27733625527Q33925492-27BE5FAB-4C6C-4900-BFA4-3591229C3BEAQ33946887-065C03F4-75C4-4AB5-9032-49E08AB07AFDQ33961507-25D12885-6CD0-43DE-AE74-351D2769D035Q33979321-4F0A170F-82C0-4EE3-B272-107AFF0439BAQ33995100-41C434DA-D008-4BF6-BEAD-61B738A13062Q34074136-0A9D528B-2AED-4EC9-AF85-3B848220A785Q34464355-CD673699-E8BC-4C25-AAC1-E59DCAA7CFD8Q34660778-EACD96F2-12F6-4E36-A29C-FC7503D5040EQ34976619-FDC93BD5-D5E5-4CDF-97E7-C7F83915D45BQ35165357-3519614C-3330-4B47-9F9E-D09A51AC7A1BQ35208107-7ADF73BD-EE1E-41BF-93E2-8F97DB22E4AAQ35534782-24225EC5-A175-4C95-A307-DCF387E692EAQ35770546-38F3896E-059E-470F-9C4D-07B6A46C2543Q35943664-47EAD6F4-2332-4D67-9307-52DB3357B903Q36411681-66B3A5FA-8917-4228-8CE7-CE9CEBED1CBEQ36608865-67A6D95B-D1D0-44EB-B7E1-32C9C1F9B921Q36638199-0AFE1468-3D1A-4BB0-9E1B-07C253942E31Q36690291-348CEB7F-5CF6-4DEF-BABF-BDC3833633DFQ37058422-E388B74B-9456-4104-8E91-3D5814179D50Q37868426-0847F7C2-B38A-4838-9A6B-9BED4AF4FE26Q37979704-14C0F879-9BA5-40B7-849D-D920B76D899DQ38932618-34DACDDE-C3D7-4471-9C7E-2DF558014D40Q39061564-C881B3A7-DE9D-4E4A-88F6-7159DCE45243Q39407246-6DCE89FB-7DC2-413B-929F-928F84771098Q39439360-239B5897-802C-4B41-A503-B78A3329491FQ39735514-911048B7-580F-4F60-BF5D-75ABE0772055Q40604278-D42BF79D-76E8-4F57-BA35-EA69C738042DQ40705242-EE3CDD6C-847A-408C-BC33-4073597D43A7Q40783234-DB2EDBF4-6A9F-466E-8CA8-3E0CE5F1E544
P2860
HIV treatment failure: testing for HIV resistance in clinical practice.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
HIV treatment failure: testing for HIV resistance in clinical practice.
@en
HIV treatment failure: testing for HIV resistance in clinical practice.
@nl
type
label
HIV treatment failure: testing for HIV resistance in clinical practice.
@en
HIV treatment failure: testing for HIV resistance in clinical practice.
@nl
prefLabel
HIV treatment failure: testing for HIV resistance in clinical practice.
@en
HIV treatment failure: testing for HIV resistance in clinical practice.
@nl
P1433
P1476
HIV treatment failure: testing for HIV resistance in clinical practice.
@en
P2093
P304
P356
10.1126/SCIENCE.280.5371.1871
P407
P577
1998-06-01T00:00:00Z